Arizona Pulmonary Specialists, Phoenix, AZ 85012, USA.
University Medical Center, Phoenix, AZ 85006, USA.
Future Cardiol. 2020 Nov;16(6):547-558. doi: 10.2217/fca-2020-0021. Epub 2020 May 11.
Despite progress over the past 30 years, pulmonary arterial hypertension remains a condition with high morbidity and mortality. Pharmacological and technological advances have shifted the approach to treating pulmonary arterial hypertension. Recent developments revolve heavily around novel routes of drug administration and delivery. In 2009, inhaled treprostinil was approved followed by oral treprostinil in 2013 providing patients with more convenient routes of administration compared with the parenteral alternatives. We are on the cusp of having the first fully implantable infusion pump for continuous intravenous treprostinil delivery. In 2019, generic treprostinil was approved, making the medication much more affordable for patients. In this review, we discuss in detail the recent developments surrounding both traditional and novel treprostinil products.
尽管在过去的 30 年中取得了进展，但肺动脉高压仍然是一种发病率和死亡率都很高的疾病。药理学和技术的进步改变了肺动脉高压的治疗方法。最近的发展主要集中在新型药物给药途径和输送方式上。2009 年，吸入性曲前列尼尔获得批准，随后在 2013 年，口服曲前列尼尔也获得批准，与传统的注射剂相比，为患者提供了更方便的给药途径。我们即将迎来第一个用于持续静脉输注曲前列尼尔的全植入式输注泵。2019 年，通用曲前列尼尔获得批准，使药物对患者更加负担得起。在这篇综述中，我们详细讨论了传统和新型曲前列尼尔产品的最新进展。
